Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RhoA Y42C inhibitor
- Development stage
- Preclinical
- Lead developer
- Revere Pharmaceuticals
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
01
Overview
RhoA Y42C inhibitor is a small molecule drug in preclinical development by Revere Pharmaceuticals for the treatment of gastric cancer, specifically targeting the mutant form of the Rho GTPase protein, RhoA with a tyrosine-to-cysteine substitution at position 42 (Y42C). This mutation is implicated in certain cancers, including diffuse gastric cancer. The drug works by selectively binding to and inhibiting the mutated RhoA Y42C protein, thereby preventing its interaction with downstream effectors involved in tumorigenesis and cell survival pathways. By blocking this mutant protein's activity, the inhibitor aims to suppress oncogenic signaling that drives cancer progression[1][2][3].
- Other names
- RhoA Y42C inhibitorRhoA/Cdc42
02
Targets
RHOA Y42C (Ras homolog family member A Y42C mutant)
Beyond the preview
Go deeper on RhoA Y42C inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RhoA Y42C inhibitor.